Ascendis Pharma A/S (ASND)
NASDAQ: ASND
· Real-Time Price · USD
175.73
-1.17 (-0.66%)
At close: Jun 23, 2025, 3:59 PM
176.00
0.15%
After-hours: Jun 23, 2025, 06:40 PM EDT
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Europe Revenue | 123.34M | 869K | 552K | 6.86M | 2.68M | 2.65M | 10.58M |
| Europe Revenue Growth | +14092.87% | +57.43% | -91.95% | +155.92% | +1.02% | -74.94% | n/a |
| North America Revenue | 233.22M | 191.68M | 44.16M | n/a | n/a | n/a | n/a |
| North America Revenue Growth | +21.67% | +334.09% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 101.05M | 78.78M | 68.13M | 74.31M | 66.78M | 63.98M | 63.61M | 70.28M | 66.54M | 56.55M | 60.67M | 56.58M | 47.42M | 48.3M | 39.28M | 35.34M | 37.25M | 20.43M | 17.52M | 20.8M | 17.91M | 17.08M | 10M | 10.96M | 10.44M | 8.37M | 6.8M | 5.23M | 4.66M | 4.09M | 2.84M | 3.23M | 3.33M | 3.29M | 2.64M | 2.67M | 2.91M | 3.47M | 1.4M | 2.14M | 2.4M |
| Selling, General, and Administrative Revenue Growth | +28.26% | +15.64% | -8.32% | +11.27% | +4.39% | +0.57% | -9.49% | +5.62% | +17.66% | -6.79% | +7.22% | +19.33% | -1.83% | +22.96% | +11.14% | -5.11% | +82.35% | +16.57% | -15.78% | +16.13% | +4.91% | +70.77% | -8.76% | +5.02% | +24.64% | +23.20% | +30.04% | +12.10% | +14.10% | +43.87% | -12.10% | -2.83% | +1.19% | +24.42% | -1.05% | -8.22% | -16.20% | +148.57% | -34.89% | -10.85% | n/a |
| Research and Development Revenue | 86.6M | 79.3M | 73.54M | 83.48M | 70.69M | 90.88M | 111.44M | 105.02M | 106.11M | 108.62M | 97.43M | 90.38M | 83.19M | 65.65M | 58.76M | 83.31M | 88.15M | 75.75M | 64.06M | 63.58M | 57.52M | 50.28M | 46.26M | 43.83M | 51.26M | 37.99M | 31.51M | 40.23M | 30.54M | 28.03M | 29.07M | 21.88M | 20.61M | 19.99M | 16.51M | 13.28M | 16.24M | 12.52M | 8.04M | 12.64M | 7.33M |
| Research and Development Revenue Growth | +9.21% | +7.82% | -11.90% | +18.10% | -22.22% | -18.45% | +6.11% | -1.03% | -2.31% | +11.48% | +7.80% | +8.64% | +26.72% | +11.73% | -29.46% | -5.49% | +16.37% | +18.25% | +0.76% | +10.54% | +14.39% | +8.69% | +5.55% | -14.50% | +34.91% | +20.58% | -21.68% | +31.75% | +8.94% | -3.55% | +32.85% | +6.17% | +3.09% | +21.08% | +24.33% | -18.24% | +29.78% | +55.70% | -36.41% | +72.36% | n/a |